Literature DB >> 14998421

Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria.

Te-Yu Hung1, Timothy M E Davis, Kenneth F Ilett, Harin Karunajeewa, Sean Hewitt, Mey Bouth Denis, Chiv Lim, Doung Socheat.   

Abstract

AIMS: To study the population pharmacokinetics of piperaquine after co-administration with dihydroartemisinin in uncomplicated malaria.
METHODS: The disposition of piperaquine was studied in 85 Cambodian patients with uncomplicated falciparum or vivax malaria treated with the piperaquine-dihydroartemisinin coformulation Artekin. All patients were given Artekin orally at 0, 6, 24 and 32 h with a total piperaquine dose of 32-35 mg base kg-1. Adults were given tablets while children received either tablets or a dispersible granule formulation. Patients underwent either intensive (17-19 samples) or sparse (2-5 samples) blood sampling schedules over 35 days and clinical/parasitological follow-up over > 28 days. Piperaquine in plasma was quantified by high performance liquid chromatography.
RESULTS: All patients achieved fever clearance within 24 h and parasite clearance within 72 h. The 28-day cure rate was 97% in adults and 98% in children. A covariate-free two-compartment population model with first-order absorption and elimination gave the most robust representation of the plasma concentration-time data in both adults and children. In adults (n = 38), the median (interquartile range) derived pharmacokinetic descriptors CL/F, Vss/F and t1/2,z were 0.9 l h-1 kg-1 (0.79-1.02 l h-1 kg-1), 574 l kg-1(371-711 l kg-1) and 23 days (19-28 days), respectively. In children (n = 47), corresponding values were 1.8 l h-1 kg-1 (1.29-2.3 l h-1 kg-1), 614 l kg-1 (332-1205 l kg-1) and 14 days (10-18 days), respectively.
CONCLUSIONS: Piperaquine is a highly lipid-soluble drug with a large Vss/F, long t1/2,z and a clearance that is markedly higher in children than in adults.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14998421      PMCID: PMC1884452          DOI: 10.1046/j.1365-2125.2003.02004.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  [In vivo sensitivity of Plasmodium falciparum to piperaquine phosphate assayed in Linshui and Baisha counties, Hainan Province].

Authors:  C X Lan; X Lin; Z S Huang; Y S Chen; R N Guo
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  1989

2.  Bisquinolines. 1. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria.

Authors:  J L Vennerstrom; W Y Ellis; A L Ager; S L Andersen; L Gerena; W K Milhous
Journal:  J Med Chem       Date:  1992-05-29       Impact factor: 7.446

3.  [Susceptibility of Plasmodium falciparum to chloroquine, piperaquine, amodiaquine, mefloquine and quinine with in vitro microtechnique in Hainan Island].

Authors:  K Y Zhang; J X Zhou; Z Wu; Q L Huang
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  1987

4.  [Sensitivity of Plasmodium falciparum to piperaquine in Baoting County, Hainan Island].

Authors:  J Z Huang; X H Lan; W Z Xu
Journal:  Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  1985

5.  [Randomised comparison on the treatment of falciparum malaria with dihydroartemisinin and piperaquine].

Authors:  X B Guo
Journal:  Zhonghua Yi Xue Za Zhi       Date:  1993-10

6.  Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria.

Authors:  W M Watkins; P A Winstanley; E K Mberu; G Kokwaro; S A Murphy; C J Newton; I Mwangi; D Forster; K Marsh
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

7.  Recent studies on antimalarial efficacy of piperaquine and hydroxypiperaquine.

Authors:  L Chen
Journal:  Chin Med J (Engl)       Date:  1991-02       Impact factor: 2.628

8.  [Sensitivity in vitro of Plasmodium falciparum to chloroquine, pyronaridine, artesunate and piperaquine in south Yunnan].

Authors:  H L Yang; P F Yang; D Q Liu; R J Liu; Y Dong; C Y Zhang; D Q Cao; H He
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  1992

9.  [Comparative study of artemisinin suppositories and piperaquine phosphate in the treatment of falciparum malaria].

Authors:  X B Guo; L C Fu
Journal:  Zhong Xi Yi Jie He Za Zhi       Date:  1989-08

10.  [Observation on the efficacy of combined use of some new antimalarials for the treatment of falciparum malaria in Hainan Province].

Authors:  L Chen; Z R Dai; Y L Qian; Z M Ma; F C Guo; Z H Liao; D D Fu; D Q Ma; X J Pang
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  1989
View more
  79 in total

1.  Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola.

Authors:  Mateusz M Plucinski; Eldin Talundzic; Lindsay Morton; Pedro Rafael Dimbu; Aleixo Panzo Macaia; Filomeno Fortes; Ira Goldman; Naomi Lucchi; Gail Stennies; John R MacArthur; Venkatachalam Udhayakumar
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Pitfalls in estimating piperaquine elimination.

Authors:  Joel Tarning; Niklas Lindegårdh; Anna Annerberg; Thida Singtoroj; Nicholas P J Day; Michael Ashton; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 3.  Piperaquine: a resurgent antimalarial drug.

Authors:  Timothy M E Davis; Te-Yu Hung; Ing-Kye Sim; Harin A Karunajeewa; Kenneth F Ilett
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.

Authors:  V Kohl; C Müller; O A Cornely; K Abduljalil; U Fuhr; J J Vehreschild; C Scheid; M Hallek; M J G T Rüping
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

5.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

6.  Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.

Authors:  Jessica Manning; Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Mary So; Darapiseth Sea; Youry Se; Sok Somethy; Sut-Thang Phann; Soklyda Chann; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mashamon Mitprasat; Raveewan Siripokasupkul; Paktiya Teja-Isavadharm; Eugene Soh; Ans Timmermans; Charlotte Lanteri; Jaranit Kaewkungwal; Montida Auayporn; Douglas Tang; Char Meng Chour; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

7.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

8.  Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.

Authors:  Srivicha Krudsood; Noppadon Tangpukdee; Sant Muangnoicharoen; Vipa Thanachartwet; Nutthanej Luplertlop; Siripan Srivilairit; Polrat Wilairatana; Shigeyuki Kano; Pascal Ringwald; Sornchai Looareesuwan
Journal:  Korean J Parasitol       Date:  2007-06       Impact factor: 1.341

9.  Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.

Authors:  Brioni R Moore; Kevin T Batty; Christopher Andrzejewski; Jeffrey D Jago; Madhu Page-Sharp; Kenneth F Ilett
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

10.  Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.

Authors:  Sant Muangnoicharoen; David J Johnson; Sornchai Looareesuwan; Srivicha Krudsood; Stephen A Ward
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.